1-20 of 52
Andreas Hüttmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Justin Ferdinandus, Helen Kaul, Alexander Fosså, Andreas Hüttmann, Felix Keil, Yon-Dschun Ko, Felicitas Hitz, Michaela Schwarz, Corinna Trenker, Andrea Kerkhoff, Peter Staib, Kai Wille, Irmgard Dresel, Dennis Hahn, Bernd Hertenstein, Peter Moosmann, Ulrich Mey, Stefan Balabanov, Tasman Armytage, Fernando Roncolato, Johannes Christian Hellmuth, Stefanie Kreissl, Michael Fuchs, Gundolf Schneider, Hishan Tharmaseelan, Dennis A Eichenauer, Bastian von Tresckow, Peter Borchmann, Paul J. Bröckelmann
Journal: Blood
Blood (2024) 144 (Supplement 1): 568.
https://doi.org/10.1182/blood-2024-207946
Published: 2024
Journal Articles

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Sophy Denker, Aitomi Bittner, Julia Kase, Mareike Frick, Jörg Hoffmann, Corinna Trenker, Ulrich Keller, Christian Bogner, Andreas Hüttmann, Jan Dürig, Martin Janz, Stephan Mathas, Reinhard Marks, Ulrike Krohn, Il-Kang Na, Paulina Richter-Pechanska, Animesh Bhattacharya, Bernhard Gebauer, Lynn Savic, Norbert Hübner, Altuna Akalin, Roland Eils, Lars Bullinger, Clemens Schmitt
Journal: Blood
Blood (2024) 144 (Supplement 1): 6188.
https://doi.org/10.1182/blood-2024-207123
Published: 2024
Journal Articles

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Jakoba J Eertink, Gerben JC Zwezerijnen, Martijn W Heymans, Simone Pieplenbosch, Sanne E Wiegers, Ulrich Dührsen, Andreas Hüttmann, Lars Kurch, Christine Hanoun, Pieternella Lugtenburg, Sally F Barrington, George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sandor Czibor, Tamás Györke, Martine E.D. Chamuleau, Otto S Hoekstra, Henrica C.W de Vet, Ronald Boellaard, Josée M. Zijlstra
Journal: Blood
Blood (2022) 140 (Supplement 1): 777–778.
https://doi.org/10.1182/blood-2022-163454
Published: 2022
Journal Articles

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Erik Van Dijk, Jurriaan Janssen, Matias Mendeville, G. Tjitske Los-De Vries, Margaretha GM Roemer, Phylicia Stathi, Julia Richter, Yong Soo Kim, Wolfram Klapper, Ulrich Dührsen, Andreas Hüttmann, P. J Lugtenburg, Josée M. Zijlstra, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau, Bauke Ylstra
Journal: Blood
Blood (2022) 140 (Supplement 1): 9261–9263.
https://doi.org/10.1182/blood-2022-160052
Published: 2022
Journal Articles

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F.M. Craig, Ulrich Duehrsen, Andreas Hüttmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh
Journal: Blood
Blood (2022) 140 (Supplement 1): 8609–8610.
https://doi.org/10.1182/blood-2022-170087
Published: 2022
Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Peter Borchmann, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Haenel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M. Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Peter Kamper, Daniel Molin, Stefanie Kreissl, Michael Fuchs, Gundolf Schneider, Andreas Rosenwald, Wolfram Klapper, Hans Eich, Christian Baues, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2022) 140 (Supplement 1): 771–773.
https://doi.org/10.1182/blood-2022-165917
Published: 2022
Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Brian Sworder, David M. Kurtz, Stefan K. Alig, Matthew J Frank, Navika D. Shukla, Andrea Garofalo, Charles Macaulay, Mohammad Shahrokh Esfahani, Mari Olsen, James Hamilton, III, Hitomi Hosoya, Mark P Hamilton, Jay Y. Spiegel, John H. Baird, Mia Carleton, Alexander F.M. Craig, Sheren F. Younes, Bita Sahaf, Natasha Sheybani, Joseph Schroers-Martin, Chih Long Liu, Jean S Oak, Michael C. Jin, Sara Beygi, Andreas Hüttmann, Christine Hanoun, Ulrich Dührsen, Jason Westin, Michael S. Khodadoust, Yasodha Natkunam, Robbie G. Majzner, Crystal L. Mackall, Maximilian Diehn, David B. Miklos, Ash A. Alizadeh
Journal: Blood
Blood (2022) 140 (Supplement 1): 1301–1303.
https://doi.org/10.1182/blood-2022-165545
Published: 2022
Journal Articles

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, Martine E.D Chamuleau, Pieternella Lugtenburg, Daphne De Jong, Bauke Ylstra, Matias Mendeville, Ulrich Dührsen, Andreas Hüttmann, Christine Schmitz, Julia Richter, Wolfram Klapper, Otto S Hoekstra, Henrica C.W de Vet, Ronald Boellaard, Josée M Zijlstra
Journal: Blood
Blood (2021) 138 (Supplement 1): 451.
https://doi.org/10.1182/blood-2021-145855
Published: 2021
Journal Articles

The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis

Luca Fischer, Linmiao Jiang, Joerg Bittenbring, Kai Hübel, Christian Schmidt, Johannes Duell, Bernd Metzner, Jürgen Krauter, Bertram Glass, Andreas Hüttmann, Kerstin Schaefer-Eckart, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Martin H. Dreyling, Eva Hoster
Journal: Blood
Blood (2021) 138 (Supplement 1): 3551.
https://doi.org/10.1182/blood-2021-148074
Published: 2021
Journal Articles

Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Jesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, Guido Kobbe, Martin Wilhelm, Bernhard Heinrich, Tobias Gaska, Helmut Forstbauer, Burkhard Schmidt, Andreas Hüttmann, Gerhard Heil, Doris M. Kraemer, William Hermann Krüger, Vanja Zeremski, Norbert Grobe, Kathleen Jentsch-Ulrich, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Paul J Bröckelmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 4533.
https://doi.org/10.1182/blood-2021-153200
Published: 2021
Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Emmanuel Bachy, MD PhD, Vincent Camus, Catherine Thieblemont, MD PhD, Rene-Olivier Casasnovas, MD, Loic Ysebaert, MD PhD, Gandhi Laurent Damaj, MD PhD, Stephanie Guidez, Gian-Matteo Pica, MD, Won Seog Kim, MD PhD, Soon Thye Lim, MBBS, MRCP, FAMS, Marc André, MD, Alejandro Martin Garcia-Sancho, MD PhD, Maria Jesus Penarrubia Ponce, MD, Philipp B. Staber, MD PhD, Judith Trotman, FRACP, Andreas Hüttmann, MD, Vittorio Stefoni, MD PhD, Alessandro Re, MD, Philippe Gaulard, MD PhD, Marie-Helene Delfau-Larue, MD PhD, Laurence De Leval, MD, Michel Meignan, MD, Ju Li, PhD, Franck Morschhauser, MD PhD, Richard Delarue, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-134440
Published: 2020
Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Paul J Bröckelmann, MD, Helen Goergen, Dipl.-Math., Ulrich Keller, Julia Meissner, MD, Karolin Trautmann, MD, Teresa V Halbsguth, MD, Stephanie Sasse, MD, Martin Sökler, MD, Andrea Kerkhoff, MD, Stephan Mathas, MD, Andreas Hüttmann, MD, Matthias Bormann, MD, Andreas Zimmermann, MD, Michael Fuchs, Bastian von Tresckow, MD, Christian Baues, MD, Andreas Rosenwald, MD, Wolfram Klapper, MD, Carsten Kobe, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-138413
Published: 2020
Journal Articles

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Nora Liebers, MD, Johannes Duell, MD, Daniel Nörenberg, MD, Eva Kaebisch, MD, Andrea Kerkhoff, MD, Fabian Acker, MD, Stephan Fuhrmann, MD, Corinna Leng, MD PhD, Manfred Welslau, MD, Jens Chemnitz, MD, Jan Moritz Middeke, MD, Thomas Weber, MD, Ralf Ulrich Trappe, MD, Roald Pfannes, MD, Ruediger Liersch, MD, Christian Spoer, MD, Niklas Gebauer, MD, Stefan Fuxius, MD, Léandra Caillé, Christiane Pott, MD PhD, Christian Koenecke, MD, Udo Holtick, Thomas Geer, MD, Ulrich Keller, MD, Rainer Claus, MD, Dimitrios Mougiakakos, MD, Stephanie Mayer, MD, Andreas Hüttmann, MD, Arne Trummer, MD, Gerald Wulf, MD, Uta Brunnberg, MD, Lars Bullinger, MD, Georg Hess, MD, Carsten Mueller-Tidow, MD, Bertram Glass, MD, Georg Lenz, Peter Dreger, MD, Sascha Dietrich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-136539
Published: 2020
Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Owen A. O'Connor, MD, Barbara Pro, MD, Tim Illidge, MD PhD, Swami P. Iyer, MD, Ranjana Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, PhD, Tatyana A. Feldman, MD, Tobias Menne, MD PhD, David Belada, MD PhD, Árpád Illés, MD PhD, Kensei Tobinai, MD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R Shustov, MD, Andreas Hüttmann, MD, Kerry J. Savage, BSc, MD MSc, Sam Yuen, MBBS, FRACP, FRCPA, Pier Luigi Zinzani, MD, Harry Miao, MD, Veronica Bunn, PhD, Keenan Fenton, MA, Michelle A. Fanale, MD, Markus Puhlmann, MD, Lorenz Truemper, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-134398
Published: 2020
Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Nicola Goekbuget, MD, Wiba Keke Wermann, Stefan Schwartz, MD PhD, Andreas Hüttmann, MD, Christoph Faul, MD, Simon Raffel, MD, Andreas Viardot, Professor Dr, Walter Fiedler, MD, Nael Alakel, MD, Matthias Stelljes, MD, Marion Subklewe, MD, Ralph Wäsch, Sonja Martin, MD, Wolfram Jung, MD, Vladan Vucinic, MD, Mustafa Kondakci, MD, Lars R. Fransecky, MD, Daniela Heidenreich, MD, Knut Wendelin, MD, Julian Hermann, Hubert Serve, MD PhD, Ralf C Bargou, MD PhD, Max S. Topp, MD, Monika Brüggemann, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-137350
Published: 2020
Journal Articles

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Catherine Thieblemont, MD PhD, Loïc Chartier, Ulrich Dührsen, Prof, MD PhD, Umberto Vitolo, MD, Sally F Barrington, Prof, MD PhD, Laetitia Vercellino, Jan Zaucha, MDPhD, Inês Patrocinio Carvalho, Gomes da Silva Maria, MD PhD, Pierre Decazes, Pierre-Julien Viailly, Herve Tilly, MD PhD, Alina Berriolo-Riedinger, Rene-Olivier Casasnovas, MD, Andreas Hüttmann, MD, Hajira Ilyas, George Mikhaeel, Prof, MD PhD, Joel Dunn, Anne Ségolène Cottereau, MD, Christine Schmitz, MD, Joseph N. Paulson, Tina G Nielsen, Michel Meignan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-136544
Published: 2020
Journal Articles

AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Stephanie Sasse, MD, Jesko Momotow, MD, Annette Plütschow, Andreas Hüttmann, MD, Nadezda Basara, MD, Christian Koenecke, MD, Sonja Martin, MD, Martin Bentz, MD, Christina Grosse-Thie, MD, Sven Thorspecken, MD, Maike de Wit, MD, Carsten Kobe, MD, Markus Dietlein, MD, Bastian von Tresckow, MD, Michael Fuchs, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-141250
Published: 2020
Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Jakoba J Eertink, MSc, Coreline N Burggraaff, MD, Martijn W Heymans, PhD, Sally F Barrington, Prof, MD PhD, George Mikhaeel, Prof, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Luca Ceriani, MD, Emanuele Zucca, MD, Robert Carr, MD, Tamás Györke, MD PhD, Stefano Fanti, Prof, MD PhD, Howard R Higley, PhD, Michael V Knopp, MD PhD, Heiko Schöder, MD, Annika Loft, MD PhD, Martin Hutchings, MD PhD, Lale Kostakoglu, Prof, MD PhD, Pieternella Lugtenburg, MD PhD, Sanne E Wiegers, MSc, Simone Pieplenbosch, MSc, Ronald Boellaard, MSc, PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Henrica C.W. de Vet, Prof, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 487.
https://doi.org/10.1182/blood-2019-122298
Published: 2019
Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Paul J Bröckelmann, MD, Helen Goergen, Dipl.-Math., Ulrich Keller, MD, Julia Meissner, MD, Rainer Ordemann, MD, Teresa V Halbsguth, MD, Stephanie Sasse, MD, Martin Sökler, MD, Andrea Kerkhoff, MD, Stephan Mathas, MD, Andreas Hüttmann, MD, Matthias Bormann, MD, Andreas Zimmermann, MD, Michael Fuchs, MD, Bastian von Tresckow, Christian Baues, MD, Andreas Rosenwald, MD, Wolfram Klapper, Carsten Kobe, Peter Borchmann, MD PhD, Andreas Engert, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 236.
https://doi.org/10.1182/blood-2019-122406
Published: 2019
Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 491.
https://doi.org/10.1182/blood-2019-129283
Published: 2019